Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2019 1
2020 2
2021 2
2022 4
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Etirinotecan pegol for the treatment of breast cancer.
López-Miranda E, Cortés J. López-Miranda E, et al. Expert Opin Pharmacother. 2016;17(5):727-34. doi: 10.1517/14656566.2016.1154537. Epub 2016 Mar 10. Expert Opin Pharmacother. 2016. PMID: 26881332 Review.
Cytological and molecular characterization of secretory breast carcinoma.
Carretero-Barrio I, Santón A, Caniego Casas T, López Miranda E, Reguero-Callejas ME, Pérez-Mies B, Benito A, Palacios J. Carretero-Barrio I, et al. Among authors: lopez miranda e. Diagn Cytopathol. 2022 Jul;50(7):E174-E180. doi: 10.1002/dc.24945. Epub 2022 Feb 14. Diagn Cytopathol. 2022. PMID: 35156343 Free PMC article. Review.
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.
Hanna GJ, Stathis A, Lopez-Miranda E, Racca F, Quon D, Leyvraz S, Hess D, Keam B, Rodon J, Ahn MJ, Kim HR, Schneeweiss A, Ribera JM, DeAngelo D, Perez Garcia JM, Cortes J, Schönborn-Kellenberger O, Weber D, Pisa P, Bauer M, Beni L, Bobadilla M, Lehal R, Vigolo M, Vogl FD, Garralda E. Hanna GJ, et al. Among authors: lopez miranda e. Cancer Res Commun. 2023 Sep 14;3(9):1853-1861. doi: 10.1158/2767-9764.CRC-23-0333. Cancer Res Commun. 2023. PMID: 37712875 Free PMC article. Clinical Trial.
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer.
Jhaveri KL, Bellet M, Turner NC, Loi S, Bardia A, Boni V, Sohn J, Neilan TG, Villanueva-Vázquez R, Kabos P, García-Estévez L, López-Miranda E, Pérez-Fidalgo JA, Pérez-García JM, Yu J, Fredrickson J, Moore HM, Chang CW, Bond JW, Eng-Wong J, Gates MR, Lim E. Jhaveri KL, et al. Among authors: lopez miranda e. Clin Cancer Res. 2024 Feb 16;30(4):754-766. doi: 10.1158/1078-0432.CCR-23-1796. Clin Cancer Res. 2024. PMID: 37921755 Free PMC article. Clinical Trial.
Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments.
Cortés A, Casado JL, Longo F, Serrano JJ, Saavedra C, Velasco H, Martin A, Chamorro J, Rosero D, Fernández M, Gion M, Martínez Jáñez N, Soria Rivas A, Alonso Gordoa T, Martínez Delfrade Í, Lage Y, López Miranda E, Olmedo ME, Reguera Puertas P, Gajate P, Molina Cerrillo J, Guerra Alia E, Fuentes Mateos R, Romero B, Rodríguez-Domínguez MJ, Vallejo A, Carrato A. Cortés A, et al. Among authors: lopez miranda e. Eur J Cancer. 2022 May;166:229-239. doi: 10.1016/j.ejca.2022.02.017. Epub 2022 Mar 1. Eur J Cancer. 2022. PMID: 35316750 Free PMC article.
Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study.
López González A, Del Barco Berrón S, Grau I, Galan M, Castelo Fernández B, Cortés A, Sánchez Rovira P, Martinez-Bueno A, Gonzalez X, García A, Gener P, Mina L, Alcalá-López D, Sampayo M, Cortés J, Pérez-Garcia JM, Llombart-Cussac A, López-Miranda E. López González A, et al. Among authors: lopez miranda e. Cancers (Basel). 2022 Nov 29;14(23):5880. doi: 10.3390/cancers14235880. Cancers (Basel). 2022. PMID: 36497361 Free PMC article.
Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors.
Saavedra C, Vallejo A, Longo F, Serrano JJ, Fernández M, Gion M, López-Miranda E, Martínez-Jáñez N, Guerra E, Chamorro J, Rosero D, Velasco H, Martín A, Carrato A, Casado JL, Cortés A. Saavedra C, et al. Among authors: lopez miranda e. Cancers (Basel). 2023 Mar 27;15(7):2000. doi: 10.3390/cancers15072000. Cancers (Basel). 2023. PMID: 37046661 Free PMC article.
A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer.
Sampayo-Cordero M, Miguel-Huguet B, Malfettone A, López-Miranda E, Gion M, Abad E, Alcalá-López D, Pérez-Escuredo J, Pérez-García JM, Llombart-Cussac A, Cortés J. Sampayo-Cordero M, et al. Among authors: lopez miranda e. Front Oncol. 2023 Jul 11;13:1048242. doi: 10.3389/fonc.2023.1048242. eCollection 2023. Front Oncol. 2023. PMID: 37496662 Free PMC article.
Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design.
Sampayo-Cordero M, Miguel-Huguet B, Pérez-García J, Páez D, Guerrero-Zotano ÁL, Garde-Noguera J, Aguirre E, Holgado E, López-Miranda E, Huang X, Malfettone A, Llombart-Cussac A, Cortés J. Sampayo-Cordero M, et al. Among authors: lopez miranda e. Contemp Clin Trials Commun. 2020 Nov 28;20:100678. doi: 10.1016/j.conctc.2020.100678. eCollection 2020 Dec. Contemp Clin Trials Commun. 2020. PMID: 33336109 Free PMC article.
15 results